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mL/min and 72.6 mL/min (p0.059) but similar at-6month, 80.2 mL/min and 72.2
mL/min (p0.167).
Conclusions: High dose atorvastatin treatment does not prevent CIN in patients receiving
primary angioplasty. However it demonstrated potential of lowering CIN in patients with
renal insufficiency and elderly.
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Background: Blood transfusion is associated with acute kidney injury (AKI) after
transcatheter aortic valve implantation (TAVI). We sought to elucidate in more detail the
relation between blood transfusion and AKI and its effects on short- and long-term
mortality.
Methods: 995 patients with aortic stenosis underwent TAVI with the Medtronic-
CoreValve or the Edwards Valve in 7 centers. AKI was defined by the Valve Academic
Research Consortium (absolute increase in serum creatinine 0.3 mg/dl (26.4 mol/l)
or 50% increase 72 hr). Logistic and Cox regression was used for predictor and
survival analysis.
Results: AKI occurred in 20.7% (n206). The number of units of blood transfusion24
hr was the strongest predictor of AKI ( 5 units, OR: 4.81 [1.45-15.95], 3-4 units, OR:
3.05 [1.24-7.53], 1-2 units, OR: 1.47 [0.98-2.22]) followed by peripheral vascular disease
(OR: 1.48 [1.05-2.10]), history of heart failure (OR: 1.43 [1.01-2.03]), leucocyte count
72 hrs after TAVI (OR: 1.05 [1.02-1.09]) and EuroSCORE (OR: 1.02 [1.00-1.03]).
Potential triggers of blood transfusion such as baseline anemia, bleeding-vascular
complications and peri-operative blood loss were not identified as predictors. Patients with
severe baseline anemia had 2.4 times less blood loss but on average received 2.3 fold more
units of blood transfusions in comparison to patients without anemia before TAVI
(p0.001). AKI and life-threatening bleeding were independent predictors of 30-day
mortality (OR: 3.04 [1.52-6.07], OR: 5.39 [2.14-13.57], respectively) while transfusion
(3 units), baseline anemia and AKI predicted mortality beyond 30 days.
Conclusions: AKI occurred in 21% of the patients after TAVI. The number of blood
transfusions but not the indication of transfusion predicted AKI. AKI was a predictor of
both short- and long-term mortality whereas blood transfusion predicted long-term
mortality. These findings indicate that outcome of TAVI may be improved by more
restrictive use of blood transfusions.
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Background: Chronic kidney disease (CKD) patients have less favorable outcomes after
ST-elevation myocardial infarction (STEMI) for yet unclear reasons.
Methods: The INFUSE-AMI trial randomized patients with STEMI due to proximal or
mid LAD occlusion to intracoronary bolus abciximab (ClearWay RX catheter) vs. no
abciximab, and to thrombus aspiration (Export) vs. no aspiration. We compared infarct
size as % of LV mass assessed by magnetic resonance imaging at 30-days, myocardial
reperfusion and incidence of adverse events between patients with vs. patietns without
CKD. CKD was defined as a creatinine clearance  60 ml/min.
Results: Patients with CKD (n59, 14.4%) were older, more often female, diabetic and
less likely to undergo angiography within 3 hours of symptom onset (50.8% vs. 72.2%,
p0.001) compared to those without CKD (n349, 85.5%). Following PCI, final
thrombolysis in myocardial infarction (TIMI) 3 flow (86.4 vs. 92.8%, p0.12) and
myocardial blush grade (MBG) 3 (64.4% vs. 70.5%, p0.35) was observed similarly in
both groups. Median infarct size was non-significantly larger in CKD patients (19.3% vs.
17.0%, p0.34). The incidence of 30-day adverse events, were significantly higher in
those with CKD (Figure). There were no significant differences in stent thrombosis,
reinfarction or revascularization between groups.
Conclusions: Differences in infarct size between patients with and without CKD
presenting with STEMI are modest and unlikely to account for the significantly higher
short-term cardiac risk in those with CKD.
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Background: Several definitions of acute kidney injury (AKI) are in use, and the optimal
absolute and relative increase of serum creatinine increase after contrast administration to
define contrast-media induced acute kidney injury (CI-AKI) is still a matter of debate.
Moreover, the prognostic relevance of AKI according to the varying definitions in STEMI
has not been established.
Methods: Serum creatinine concentration data within 48h after coronary angiography
was present in 2975 STEMI pts in the HORIZONS-AMI trial. Patients were analyzed
according to different AKI definitions (AKIN-, modified AKIN- (mAKIN), Waikar-
Bonventre (W-B), percent-changes of creatinine (25%, 26-50%; 51-75%; 75%) and
to the commonly used “standard-definition” of a relative increase in serum creatinine of
25% or an absolute increase of 0.5 mg/dL). The primary endpoint was all-cause
mortality at 3 years.
Results: Depending on definitions the incidence of CI-AKI ranged from 5.0% to 15.5%.
Similarly, 3-year mortality rates differed substantially with respect to the different CI-AKI
definitions (Table). Absolute changes of creatinine were strongly associated with all-cause
mortality, starting with an increase of 0.3mg/dl absolute increase of creatinine above
baseline (HR 3.68 p0.001; Figure) – the cutoff level used in the AKIN- and modified
AKIN-definitions. The increased risk associated with 0.3mg/dl absolute increase of
creatinine was independent of the amount of contrast-media used.
AKIN mAKIN W-B
Percent-
changes Standard
no CI-AKI 4.2 4.2 4.8 4.5 4.5
CI-AKI I 24.0 14.5 23.0 8.7 16.0
CI-AKI II 60.0 23.0 58,5 21.4
CI-AKI III 36.5 55.6 53.5 47.3
p-value p0.001 p0.001 p0.001 p0.001 p0.001
Conclusions: The modified AKIN criteria might be the optimal definition for contrast-
induced AKI after primary PCI in STEMI.
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